Chemclin Diagnostics Co. Ltd. A (688468) - Total Liabilities

Latest as of March 2026: CN¥344.10 Million CNY ≈ $50.35 Million USD

Based on the latest financial reports, Chemclin Diagnostics Co. Ltd. A (688468) has total liabilities worth CN¥344.10 Million CNY (≈ $50.35 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Chemclin Diagnostics Co. Ltd. A annual equity growth to track the company's year-over-year net asset growth rate.

Chemclin Diagnostics Co. Ltd. A - Total Liabilities Trend (2017–2025)

This chart illustrates how Chemclin Diagnostics Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. See 688468 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.

Chemclin Diagnostics Co. Ltd. A Competitors by Total Liabilities

The table below lists competitors of Chemclin Diagnostics Co. Ltd. A ranked by their total liabilities.

Company Country Total Liabilities
Ausgold Ltd
AU:AUC
Australia AU$23.51 Million
Clearfield Inc
NASDAQ:CLFD
USA $20.74 Million
Beijing AriTime Intelligent Control Co Ltd
SHG:600560
China CN¥1.43 Billion
Xunlei Ltd Adr
NASDAQ:XNET
USA $234.06 Million
Thaicom Public Company Limited
BK:THCOM
Thailand ฿5.46 Billion
Autolus Therapeutics plc
F:6A3A
Germany €410.94 Million
Pacific Biosciences of California
NASDAQ:PACB
USA $780.00 Million
Hotel Majestic Cannes
PA:MLHMC
France €33.61 Million

Liability Composition Analysis (2017–2025)

This chart breaks down Chemclin Diagnostics Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Chemclin Diagnostics Co. Ltd. A market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 4.77 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.24 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.20 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Chemclin Diagnostics Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Chemclin Diagnostics Co. Ltd. A (2017–2025)

The table below shows the annual total liabilities of Chemclin Diagnostics Co. Ltd. A from 2017 to 2025.

Year Total Liabilities Change
2025-12-31 CN¥350.05 Million
≈ $51.22 Million
-15.82%
2024-12-31 CN¥415.85 Million
≈ $60.85 Million
-3.68%
2023-12-31 CN¥431.76 Million
≈ $63.18 Million
+105.02%
2022-12-31 CN¥210.59 Million
≈ $30.82 Million
+38.33%
2021-12-31 CN¥152.23 Million
≈ $22.28 Million
+27.43%
2020-12-31 CN¥119.46 Million
≈ $17.48 Million
-5.50%
2019-12-31 CN¥126.42 Million
≈ $18.50 Million
+56.33%
2018-12-31 CN¥80.87 Million
≈ $11.83 Million
+22.24%
2017-12-31 CN¥66.15 Million
≈ $9.68 Million
--

About Chemclin Diagnostics Co. Ltd. A

SHG:688468 China Diagnostics & Research
Market Cap
$362.15 Million
CN¥2.47 Billion CNY
Market Cap Rank
#13923 Global
#4144 in China
Share Price
CN¥6.17
Change (1 day)
+0.33%
52-Week Range
CN¥5.55 - CN¥8.94
All Time High
CN¥27.99
About

Chemclin Diagnostics Co., Ltd. engages in the research and development, production, and sale of clinical immune chemiluminescence diagnostic reagents and instruments. Its products include LiCAA series of diagnostic reagents based on photo-induced chemiluminescence and CC series based on enzymatic chemiluminescence diagnostic reagents and instruments, primarily used for infectious diseases, such a… Read more